Kala Pharmaceuticals Inc (NASDAQ:KALA)., a micro-cap biotech company valued at $40.13 million, has seen its stock reach a 52-week high, hitting an impressive $8.81. This peak reflects a significant ...

Zentalis Pharmaceuticals said it would cut 40% of its workforce as part of a restructuring to support the late-stage development of its cancer-drug azenosertib.